Galectin Therapeutics (GALT), the developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced the appointment of Jack Callicutt to the position of Chief Financial Officer, effective July 1, 2013.
Callicutt will lead the Company's financial activities, including financial reporting, accounting, risk management, public company governance, interaction with capital markets, and public and investor relations.
Callicutt has over 22 years of public and private company experience including more than a decade of audit, tax, and SEC registrant experience with a major accounting firm. He was most recently CFO for REACH Health, Inc., a telemedicine firm, where he completed a $4 million private placement.
Previous positions include CFO of Vystar Corporation, a public medical device company whose latex products are devoid of antigenic proteins, where he led all areas of financial reporting, accounting, treasury, risk management and administration and secured over $4.5 million in financing. Previous experiences also include CFO roles at private companies including IVOX and Tikvah Therapeutics, and at Coratus Genetics, a publicly traded biopharmaceutical company.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org